HIGHLIGHTS
- who: Elena Verzoni from the dei Tumori di Milano, Via Venezian, Milan, Italy have published the paper: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program, in the Journal: (JOURNAL)
- what: Given the controversy over the potential association of irAEs with favorable clinical outcomes and the discordant conclusions obtained in different cancer populations, here the authors report the results of a secondary analysis of the Italian EAP for nivolumab in mRCC patients, with the specific aim . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.